key: cord-0820467-thwwmjdc
authors: Garfield, Joseph M.
title: One-year multidisciplinary follow-up of Covid 19 patients requiring invasive mechanical ventilation
date: 2021-12-24
journal: J Cardiothorac Vasc Anesth
DOI: 10.1053/j.jvca.2021.12.020
sha: e200035d28dac7ae1403397916241b688a28d055
doc_id: 820467
cord_uid: thwwmjdc

nan

This issue contains an important and thought-provoking article about long term clinical and behavioral outcomes of seriously ill Covid 19 patients: "One-year multidisciplinary follow-up of Covid 19 patients requiring invasive mechanical ventilation 1 ". Covid 19 is a pandemic disease entity with global clinical, economic and societal consequences.

This study was undertaken in response to a surge of Covid 19 cases in Italy between February 27 and April 25,2020 which occurred after the initial outbreak in Wuhan, China and before the first variants, especially the Delta and Omicron variants, emerged 1 . At the time this study was conducted, there were almost no long-term data available on quality of life and cognition in patients who survived Covid 19 ARDS, after initial onset of the disease. Of the 116 patients admitted to the study institution's ICU during the study period with Covid 19 ARDS who received at least one day of mechanical ventilation (IMV), 61 (52.6%) survived and were discharged. The discharged patients were 89% male with a mean age of 56  11.9 years. The authors of this study used telephone interviews to administer validated behavioral and psychological measures to assess overall quality of life and functional ability in their subjects' daily lives at 2 and 12 months after discharge. Of the 61 survivors, 56 (91.8%) consented to the telephone assessments, which is impressive for survey research, and 36 (64%) of the respondents agreed to a follow-up CT scan. More than 80% reported good functional recovery and no difficulties in pursuing their usual activities. Most of the respondents (91.7%) reported no dyspnea at rest, and only 5 ( 8.9%) respondents reported severe anxiety/depression. The reported findings are particularly interesting in that they show that the study population had an overall good functional recovery. These positive outcomes may be partly a function of the study population's demographics, i.e., predominantly late middle-aged males.

This study is one of the first large scale systematic investigations to address the issue of longterm quality of life and daily functioning in those surviving severe ARDS stemming from Covid 19. One of the more troubling aspects of the disease is that a significant percentage of patients who manifest different degrees of disease severity and clinical recovery suffer from a variety of long-term behavioral issues that significantly impair quality of life and ability to perform activities of daily living 2 . Although we are still in the early stages of characterizing these problems, this article is a significant first step in quantifying their incidence and clinical effect. This has assumed particular importance, especially in the United States, where Long-Haul Covid, in conjunction with the CDC and the US Dept. of Human Health Services, is now classified as a distinct disease entity. The present study covers outcomes at 2 and 12 months 1 . Future studies will benefit by accurately delineating length and severity of long-haul Covid by following patients for several years using measures such as those in the current article, that will allow meaningful comparisons and meta-analyses 2 3 .

There are several similar studies of the first wave of Covid 19 patients in the literature that report outcomes at 6 months, rather than one year 4 5 6 . Although differing relative to geographical region, institution, study population, severity of disease, assessment instruments and comorbidities, they all showed appreciable incidences of somatic and psychological deficits at 6 months, apparently occurring in patients with varying degrees of Covid severity. The Italian study, on the other hand, demonstrated that these symptoms largely abated by 12 months in a population of seriously ill patients, an encouraging finding. The reasons for this disparity are not clear, which indicates the pressing need for further, larger studies to elucidate underlying mechanisms.

The literature shows that a number of co-morbidities, e.g., obesity, hypertension, diabetes, contribute to clinical and behavioral sequelae in Covid19 patients, and patients with these comorbidities often have worse outcomes 7 . A significant number of patients with these comorbidities should be included in long term outcome studies, so that accurate, quantitative information will be available to guide future clinicians in the treatment of Covid 19 patients.

In addition to comorbidities, future studies will need to include a greater degree of diversity in study populations. There should also be an attempt to ensure that gender, ethnic and socioeconomic groups are adequately included, so that appropriate statistical analyses can be performed. Sub-populations of particular interest include the elderly, women, minorities and economically disadvantaged 8 . Outcome studies should also be conducted at more than one institution. While multi-institutional studies do not ensure demographic diversity, they have geographical diversity and avoid some of the subtle limitations of studying patients from a single institution.

Since these original investigations, the Covid 19 virus has mutated into several variants, the most prevalent currently being the Delta and Omicron. Vaccines are also now available as are antiviral oral medications for patients when symptoms first appear. Patient populations can be divided into the vaccinated, the vaccinated who have received boosters, the unvaccinated and those who are vaccinated but have breakthrough infections. Many institutions now have clinics to treat patients who have recovered from Covid 19 but are still experiencing problems from their illness. In order to get conclusive information about the long-term clinical and behavioral effects of Covid 19 and its variants and how these effects may be mitigated by the vaccines and other treatments, we need to design and perform further rigorous outcome studies. These will serve to differentiate patients that fall into the above categories and also address a number of issues that were not covered in the initial investigations.

The pioneering Italian study serves as a blueprint for the type of rigorous outcome studies that need to be performed across sub-populations in order to truly understand the implications of Covid 19's societal burden as well as create insights into causality.

One-year multidisciplinary follow-up of Covid 19 patients requiring invasive mechanical ventilation

Psychiatric and neuropsychiatric presentations associated with severe coronavirus infections: a systematic review and meta-analysis with comparison to the Covid 19 pandemic

Applying the WHO ICF Framework to the Outcome Measures Used in the Evaluation of Long-Term Clinical Outcomes in Coronavirus Outbreaks

6-month consequences of Covid 19 in patients discharged from hospital: a cohort study

Six-Month Quality of Life in Covid 19 Intensive Care Unit Survivors

Sequelae in Adults at 6 Months After Covid 19 Infection

Association of pre-existing comorbidities with mortality and disease severity among 167,500 individuals with Covid 19 in Canada: A population-based cohort study

Racial and Ethnic Disparities in Rates of Covid 19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From